---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-068816"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:03:35.448358+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# KalVista hits Phase 3 attack target for sebetralstat; NDA on track for H1 2024

## Summary
- Phase 3 KONFIDENT trial achieved targeted number of attacks; data readout early 2024, NDA filing expected H1 2024.
- Received Orphan Drug Status from Switzerland for sebetralstat, providing 15-year market protection.
- Net loss of $27.7M ($0.80/share) for Q2 FY24 vs. $22.3M ($0.90/share) year ago; revenue nil.
- Cash, equivalents and marketable securities $103.2M at Oct 31, 2023, down from $149.4M at Apr 30, 2023.
- R&D expenses $19.1M; G&A expenses $10.7M, both up YoY due to trial costs and commercial build-out.

## SEC filing metadata
- accession: 0000950170-23-068816
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017023068816/0000950170-23-068816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017023068816/kalv-20231207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-068816
- JSON: https://secwatch.observer/filing/0000950170-23-068816.json
- Plain text: https://secwatch.observer/filing/0000950170-23-068816.txt

## Key facts
- Earnings Releases
  KalVista Pharmaceuticals, Inc. reported the three months ended October 31, 2023 results: revenue No revenue was recognized, net income Net loss was $27.7 million, EPS $(0.80) per weighted average basic and diluted share.
  - Period: the three months ended October 31, 2023
  - Revenue: No revenue was recognized
  - Net income: Net loss was $27.7 million
  - EPS: $(0.80) per weighted average basic and diluted share
  - Result: reported results
  source text: On December 7, 2023, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the fiscal quarter ended October 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023068816/0000950170-23-068816-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.